JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed in a Phase Ib clinical study for its small-molecule aurora A kinase (AURKA) inhibitor, VIC-1911. This trial marks a significant step in the development of the drug, which is being investigated for its potential in treating advanced non-small cell lung cancer (NSCLC) that is resistant to EGFR-TKI inhibitors.
Study Design and Objectives
The Phase I study is a multi-center, open-label, dose escalation and expansion study aimed at assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of VIC-1911 when combined with osimertinib in patients with EGFR-TKI resistant advanced NSCLC. This approach is crucial for understanding how VIC-1911 can potentially improve outcomes for patients who have not responded to existing treatments.
VIC-1911’s Clinical Pipeline
VIC-1911 is also the subject of a Phase I/II clinical study in combination with cyclophosphamide and Sirolimus as a prevention measure for graft versus host disease (GVHD) following myeloablative allogeneic hematopoietic stem cell transplantation. This study is another example of the drug’s potential versatility in addressing different therapeutic areas. Additionally, VIC-1911 is being investigated in a Phase I study as a monotherapy or in combination with sotorasib for the treatment of KRAS G12C mutant NSCLC in the United States.
Conclusion
The initiation of the Phase Ib study for VIC-1911 is an important milestone for JS InnoPharm as it seeks to expand the therapeutic options for patients with advanced NSCLC. With multiple clinical studies underway, VIC-1911 shows promise in addressing various cancer treatments, highlighting JS InnoPharm’s commitment to innovation in oncology.-Fineline Info & Tech
